InvestoGain

Investogain Pty Limited
AFS Licence No. 334036

All correspondence to:
admin@delisted.com.au
or by mail to:
PO Box 400
Crows Nest NSW 1585

26 April 2025

Name:	PSIVIDA CORP. (PVA)
Date of Listing:	12 June 2008
Date of Delisting:	07 May 2018

Stock Exchange Status: (updated daily)

This entity was delisted from the Australian Securities Exchange on 07 May 2018.

Legal Status: (updated monthly)

ACN: 130 843 177
Registration Date: 29 April 2008
Deregistration Date: 28 May 2019

This entity was deregistered on 28 May 2019. It has thus ceased to exist.

Capital Gains Tax (CGT) Status: (updated at least quarterly)

This entity was deregistered on 28 May 2019. Deregistration is a Capital Gains Tax Event. In our opinion you are entitled to crystallise any capital loss in the tax year that deregistration occurs providing you have not previously done so. If you did not crystallise your loss in the tax year the entity was deregistered, you may seek to re-open that year’s assessment but anyway should seek professional advice as to how best to proceed.

Updates, corrections, disagreements please email to admin@delisted.com.au

Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.

Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.

Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.

PSIVIDA CORP.(PVA)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

Shareholder links

Our website ranking of PVA:

(4 out of 5)

COMPANY WEBSITE:

PVA website

PVA email

PVA investorRelations

PVA annualreports

PVA directors

REGISTRY:

Level 17, 221 St Georges Terrace, Perth WA 6000

Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail

Company details

Address: c/- Blake Dawson, Level 37, 101 Collins Street, MELBOURNE, VIC, AUSTRALIA, 3000
Tel: (08) 9227 8327 Fax: (08) 9227 6838

Date first listed: 12/06/2008
Company Secretary:
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: The Company is the successor entity to pSivida Limited (ASX code: PSD), an ASX listed pharmaceutical and biotechnology development company which undertook a restructure by way of scheme of arrangement resulting in it becoming a wholly owned subsidiary of

News & Events

Expand this box to read and print

company deregistered today	28/05/2019
delisted from the close of trading on Monday, 07 May 2018 pursuant to Listing rule 17.11.	07/05/2018
we understand the company delisted because of a significant decrease in the proportion of the Company's Common Stock held by CDI holders, poor liquidity on the ASX, spending of about AUD100,000 a year on maintaining its listing on the ASX as a result of both direct and indirect costs and further fundraising will be more likely to be successful if the Company is not listed on the ASX (the company now called EyePoint Pharmaceuticals, Inc. trades on Nasdaq as "EYPT")	07/05/2018
The securities of EyePoint Pharmaceuticals, Inc (formally pSivida Corp) will be suspended from quotation immediately under Listing Rule 17.2, at the request of the Company pursuant to the announcement dated 4 April 2018, pending delisting of the Company from the official list at the close of trade on Monday, 7 May 2018.	30/04/2018
The suspension of trading in the securities of EyePoint Pharmaceuticals, Inc (formally pSivida Corp) will be lifted immediately, following the release of the Company's response to an ASX price and volume query.	26/04/2018
The company issues a response to ASX Price and Volume Query.	26/04/2018
The securities of EyePoint Pharmaceuticals, Inc (formally pSivida Corp) will be suspended from quotation immediately, in accordance with Listing Rule 17.3. The securities will remain suspended until ASX receives a response to its price and volume query.	26/04/2018
the Company has changed its name to EyePoint Pharmaceuticals, Inc. and, as part of the name change, the Company's ticker symbol on the Nasdaq Global Market ("NASDAQ") has been changed from "PSDV" to "EYPT" effective on and from 2 April 2018. Trading of shares of the Company's common stock ("Common Stock") on the NASDAQ will be unaffected by the name and ticker symbol changes and will continue during and after the ASX delisting process. The Company's ASX ticker symbol, PVA, will remain unchanged	29/03/2018
listed entity carried for record purposes only - we understand that shareholders in pSivida Limited received one CDI in pSivida Corp for every 40 shares they held	12/06/2008

ASX Announcements (courtesy of ASX)

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

Company Updates

Post your comments here

Please read our Terms before posting comments.

Click here for free access to this company's:
ASX, Legal & CGT Status

Directors' on-market share transactions (last 5)

Purchases Sales

DATE	DIRECTOR	NUMBER	PRICE	AMOUNT
01/10/2012	Paul Hopper	10,000	$1.615 CDI	$16,150.00

Click here for the last 20 transactions all companies

Directors & Executives (current)

NAME	TITLE	DATE OF APPT
David Mazzo	Non Exec Chairman	25/07/2005
Laurence Freedman	Vice President, General Counsel	23/05/2006
Len Ross	Finance Director	19/11/2009
Nancy Lurker	Director, CEO	16/09/2016
Jay Duker	Director	28/09/2016
Douglas Godshall	Director	07/03/2012
Kristine Peterson	Director	27/06/2017
James Barry	Director	10/09/2014
Michael Rogers	Director	27/07/2005
Brian Leedman	Investor Relations
Charles Baird	Local Agent
Lori Freedman	Company Secretary

Date of first appointment, title may have changed.

Directors & Executives (former)

NAME	TITLE	DATE OF APPOINTMENT	DATE OF RESIGNATION

Date of first appointment, title may have changed.